An interventional study of Repetitive transcranial magnetic stimulation (rTMS) in Chonic Stroke Patients With Motor Impairment of Upper Limb, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Institut National de la Santé Et de la Recherche Médicale, France.
Among the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 13th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →3 of the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France are open now, in 1 country. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–70
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 39 across the 10 interventional studies, 81 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
2 of the studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06599931Institut National de la Santé Et de la Recherche Médicale, FranceCerebello-motor Neuromodulation After Stroke. CERSTIM. | 2027-01-30 |
| NCT05277519Institut National de la Santé Et de la Recherche Médicale, FranceNeuroplasticity After Proprioceptive Rehabiliation | 2027-06-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebrovascular accidents (strokes) are a major public health issue. Stroke is the 3rd leading cause of death and the leading cause of disability and loss of autonomy. In France, there are currently 130,000 new cases per year, and the aging of the population will lead to an increase in this number over the next few years. Among post-stroke impairments, motor deficit of the upper limb is the most common disability, affecting 73-88% of first-time stroke patients and 55-75% of chronic patients. Associated deficits can complicate rehabilitation management and affect recovery. The clinical profile of patients with motor deficits is therefore varied and complex, requiring an individualized approach. At present, only physiotherapy is recommended, with modest results.
Repeated transcranial magnetic stimulation is a therapy that can improve motor recovery, but currently has a low level of evidence according to the HAS (French Hight Health Authority), notably because of variability in efficacy due to heterogeneity in the clinical profile of patients. Nevertheless, it is still recommended for the recovery of cognitive functions, but also for resistant depression, and could be used to stimulate motor imagery (MI). MI training also has the advantage of stimulating the motor network. Difficult to achieve for a number of patients, the use of rTMS could facilitate this cognitive task and, in particular, provide better access to brain-computer interfaces (BCI). Indeed, among the innovative rehabilitation therapies, BCIs have emerged as the most promising. By translating brain activity during a cognitive task into a command such as electrical muscle stimulation, BCIs would restore the damaged motor network and induce motor recovery. The main obstacle to their widespread use in clinical practice is their lack of reliability, as almost 30% of patients are unable to control them correctly, either because of difficulty in performing the MI task, or because of difficulty in identifying a universal brain signature.
The BCINET project aims to improve the reliability of BCIs in two ways: by improving detection of the motor imagination task using new brain signatures, and through cognitive facilitation using rTMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic stroke patients with motor deficit of upper limb
The probe will be placed on the healthy motor cortex at the Extensor Carpi Radialis " hotspot " level. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect
Device: Repetitive transcranial magnetic stimulation (rTMS)
The probe will be placed on the injured motor cortex at the Extensor Carpi Radialis " hotspot " level. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect
Device: Repetitive transcranial magnetic stimulation (rTMS)
The probe will be placed at the stimulation site identified by control theory. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect
Device: Repetitive transcranial magnetic stimulation (rTMS)
The repeated stimulations will be carried out using an eight-part probe detected by the infrared camera ("eight shaped tracked coil"), connected to a Rapid 2 stimulator (Magstim Company, Whitland, UK). The stimulation will be performed manually or with robotic assistance using TMS-Robot (Axilum Robotics, SCHILTIGHEIM, France)
Measuring primary BCI performance
Accuracy was choosen, which correspond to the percentage of correct detection of mental tasks (either MI or rest) on all tasks performed during the session.
Time frame: 6 weeks, 18 weeks
Measuring secondary BCI performance by using the sensitivity indicator " recall "
Sensitivity is the proportion of correct IM task detections out of all real IM tasks
Time frame: Up to 20 weeks
Measuring secondary BCI performance by using the positive predictive value " precision "
The positive predictive value is the proportion of correct MI detections out of all tasks detected by algorithm
Time frame: Up to 20 weeks
Measuring secondary BCI performance by using the Run-Wise Cross-Validation method
To reduce the the intersessional variabilityy in accurnc, we use the Run-Wise Cross-Validation (RWCV CA) method will be used.
Time frame: Up to 20 weeks
Assessment of the motor function using the Fugl-Meyer upper limb motor subscale (UE-FMA)
Rough assessment of dexterity during goal directed movements
Time frame: Inclusion visit, 6 weeks
Assessment of the motor function using Box and Block Test (BBT)
Rough assessment of dexterity during goal directed movements
Time frame: Up to 20 weeks
Assessment of the motor function using the Grip and Pinch force
Pure evaluation of the finger flexion force using dynamometer
Time frame: Up to 20 weeks
Evaluation of spasticity
Will be assessed and monitored using the modified Ashworth scale (mAs score)
Time frame: Inclusion visit, 6 weeks
Hemineglet assessment by text reading test
A text reading test in which the number of words correctly read in one minute and the percentage of words omitted will be counted
Time frame: Up to 20 weeks
Hemineglet assessment by line bissection test
The measurement of the center deviation will be quantified
Time frame: Up to 20 weeks
Analysis of spectral power
Measurement of the power of electrical signal produced by the brain depending on frequency
Time frame: Up to 20 weeks
Phase-Amplitude Coupling (PAC) analysis
By analysing the phase-amplitude relationships of different frequency bands in the EEG signal
Time frame: Up to 20 weeks
Quantification of the functional connectivity (FC)
To quantify this communication, we will use a correlation matrix constructed by calculating the coefficients of spectral coherence between all of EEG channels pairs
Time frame: 2 minutes before starting rTMS stimulation
Measurement of cortical excitability (Motor Evoked Potentials)
Assessment of the amplitude of MEPs per single shock TMS and representes the therapeutic target of rTMS
Time frame: Inclusion visit, 6 weeks, 18 weeks
Started Apr 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →